Clinical Trials
138 trialsR-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Fujian Medical University
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
COPA-R-CHOP
University Hospital Muenster
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
M.D. Anderson Cancer Center
LYMPHODTECT
Centre Antoine Lacassagne
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Changhai Hospital
A Combination Study of CAR-T Therapy in r/r B-NHL
Ruijin Hospital
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Ruijin Hospital
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
Ruijin Hospital
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
Ruijin Hospital
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma
Chongqing University Cancer Hospital
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
CONTROL
Humanitas Hospital, Italy
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
University of Bologna
Relyage
Centre Hospitalier Universitaire, Amiens
CICPD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Reduced Chemotherapy in Low Risk DLBCL
Ruijin Hospital
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
QUALITOP CAR-T
Hospices Civils de Lyon
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Ruijin Hospital
Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients
The Catholic University of Korea
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Zhejiang University
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
First Affiliated Hospital of Wenzhou Medical University
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
AEDV Registry of Primary Cutaneous Lymphoma
Fundación Academia Española de Dermatología
CNSctDNA
Herlev Hospital
ZR-CHOP in DLBCL With Specific Gene Abnormality
Fudan University
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL
The Affiliated Hospital of Qingdao University
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Zhejiang University
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
Ruijin Hospital